Document:

Unassociated Document

OMNIBUS AMENDMENT NO. 1

 TO CONVERTIBLE PROMISSORY NOTES

THIS OMNIBUS AMENDMENT TO CONVERTIBLE PROMISSORY NOTES (this “Amendment”), dated as of September 30, 2011, by and among WAFERGEN BIO-SYSTEMS, INC., a Nevada corporation (the “Borrower”), and the other signatories hereto (such other signatories collectively, the “Holder Signatories,” and each, a “Holder Signatory”).

W I T N E S S E T H:

WHEREAS, reference is made to (i) that certain Purchase Agreement, dated as of May 25, 2011 (the “Purchase Agreement”) by and among the Borrower and the investors named in the Schedule I attached thereto (including, among others, the Holder Signatories) and (ii) each of those certain Convertible Promissory Notes Due November 27, 2014 (collectively, the “Notes,” and each, a “Note”), issued pursuant to the Purchase Agreement on May 27, 2011 by the Borrower to the holders (collectively, the “Holders,” and each, a “Holder”) listed on Exhibit A hereto in the original principal amounts set forth on such Exhibit A (which such Exhibit A is incorporated herein by reference and made a part hereof);

WHEREAS, the parties have determined that the deletion of the provisions in Section 7(c)(vii) of the Notes may facilitate a future potential listing of the Borrower on a securities exchange; and

WHEREAS, the parties hereto wish to amend each of the Notes to delete such Section 7(c)(vii) of each of the Notes;

WHEREAS, pursuant to Section 5 of each of the Notes such amendment may be effected by the Borrower and the Required Holders (as defined in such Section 5) and any such amendment so effected shall be binding upon the Borrower and the Holder of each Note;

WHEREAS, the Holder Signatories constitute the Required Holders for purposes of such amendment;

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound and to legally bind the Holder of each Note, hereby agree as follows:

SECTION 1.                      Amendment of the Notes.  Each of the Notes is hereby amended to delete in its entirety Section 7(c)(vii) thereof and to renumber the immediately following sections (viii) and (ix) as (vii) and (viii) respectively.

SECTION 2.                      Notice of Amendment.  The Borrower shall give each Holder notice of this Amendment along with a copy hereof in accordance with the notice provisions of Section 16 of the Notes.  For the avoidance of doubt, the parties hereto agree that the effectiveness of this Amendment is not conditioned upon the giving of such notice.

 

  

  

  

 

SECTION 3.                      Effect of Amendment.  Except as expressly modified in this Amendment, all of the terms, provisions and conditions of each of the Notes shall remain unchanged and in full force and effect and each of the Notes is hereby ratified and confirmed and shall remain in full force and effect according to its terms.  Except as expressly set forth in this Amendment, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power, claim (whether currently known or unknown) or remedy of any Holder under any Note or under any of the other Transaction Agreements (as defined in the Purchase Agreement), nor constitute a waiver of any provision of any Note or any other Transaction Agreement.  This Amendment shall not constitute a course of dealing with any Holder Signatory or any other Holder at variance with any Note or any other Transaction Agreement except as expressly set forth herein.  The Borrower acknowledges and expressly agrees that each Holder (i) reserves the right to, and does in fact, require strict compliance with all terms and provisions of the Note issued to such Holder and each other Transaction Agreement and (ii) reserves the right to assert any claim (whether currently known or unknown) pursuant to such Note or any other Transaction Agreement.

SECTION 4.                      Headings.  The headings in this Amendment are solely for convenience and will not be given any effect in the construction or interpretation of this Agreement.

SECTION 5.                      Counterparts.  This Amendment may be executed in one or more counterparts, which may be delivered by facsimile transmission, each of which will be deemed an original and all of which will constitute one and the same Amendment.

SECTION 6.                      Successors.  This Amendment shall be binding upon and shall inure to the benefit of the Borrower, the Holders and their respective successors and permitted assigns, if any.

SECTION 7.                      GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, CONSTRUED IN ACCORDANCE WITH, AND ENFORCED UNDER, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS OR INSTRUMENTS ENTERED INTO AND PERFORMED ENTIRELY WITH SUCH STATE, EXCEPT TO THE EXTENT THE GENERAL CORPORATIONS LAW OF THE STATE OF NEVADA SHALL APPLY.

[Remainder of Page Intentionally Left Blank]

 

  

  

  

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

	 	

BORROWER:

	 
	 	 	 	 
	 	

WAFERGEN BIO-SYSTEMS, INC.

	 
	 	 	 	 
	
 

	
By: 

	/s/ Alnoor Shivji	 
	 	 	Name:	Alnoor Shivji	 
	 	 	Title:	Chief Executive Officer	 
	 	 	 	 

 

[FIRST SIGNATURE PAGE TO OMNIBUS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTES]

 

  

  

  

 

	 	

HOLDER SIGNATORIES:

	 
	 	 	 	 
	 	

BIOMEDICAL VALUE FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

	 	

BIOMEDICAL INSTITUTIONAL VALUE FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

	 	

BIOMEDICAL OFFSHORE VALUE FUND, LTD.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

	 	

WS INVESTMENTS III, LLC

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

	 	

DAVID J. MORRISON

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

 

[SECOND SIGNATURE PAGE TO OMNIBUS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTES]

 

  

  

  

 

	 	

CLASS D SERIES OF GEF-PS, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

	 	

LYRICAL MULTI-MANAGER FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 
	 	 	 	 

 

 

[THIRD SIGNATURE PAGE TO OMNIBUS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTES]

  

  

  

 

	 	

DEERFIELD SPECIAL SITUATION FUND, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

	 	

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL, LIMITED

	 
	 	 	 	 
	
 

	
By: 

	/s/ James E. Flynn	 
	 	 	Name:	James E. Flynn	 
	 	 	Title:	Director	 
	 	 	 	 

 

	 	

DEERFIELD PRIVATE DESIGN FUND II, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

	 	

DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

 

[FOURTH SIGNATURE PAGE TO OMNIBUS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTES]

  

  

  

 

	 	

THE SHIVJI FAMILY TRUST DATED JUNE 12, 2000

	 
	 	 	 	 
	
 

	
By: 

	/s/ Alnoor Shivji 	 
	 	 	Name:	Alnoor Shivji	 
	 	 	Title:	Trustee	 
	 	 	 	 

[FIFTH SIGNATURE PAGE TO OMNIBUS AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTES]Unassociated Document

 

 

 

	
Dated:  

	
September 30, 2011

 

	
To:

	
WaferGen Bio-systems, Inc.

	
  

	
7400 Paseo Padre Parkway

	
  

	
Fremont, CA  94555

	
  

	
Attention:  Don Huffman, Chief Financial Officer

 

Dear Don,

 

Reference is made to that certain letter agreement (the “Letter Agreement”), dated May 27, 2011, from the Investors who have executed the signature pages thereto (collectively, the “Investors”) and certain other undersigned individuals (collectively, the “Management Members”) to WaferGen Bio-systems, Inc. (the “Company”).

 

Subject to the Company’s agreement hereto by its execution of this letter below where indicated, the Investors and the Management Members agree with each other and the Company that the Letter Agreement shall be terminated, effective as of the date hereof.

The parties hereto agree that in case, at any time after the date hereof, any further action is necessary or desirable to carry out the purposes and intent of this letter, the parties will take such further action as any party or parties may reasonably request.  This letter may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Any signature page of any such counterpart, or any electronic facsimile thereof, may be attached or appended to any other counterpart to complete a fully executed counterpart of this letter, and any telecopy or other facsimile transmission of any signature shall be deemed an original.  This letter shall be binding upon each party’s successors and assigns.

 

  

  

  

 

Please confirm your agreement with the foregoing by signing and returning to Great Point Partners, LLC the duplicate copy of this letter agreement enclosed herewith.

 

 

	 	Very truly yours,	 
	 	 	 
	 	 	 
	 	INVESTORS:	 
	 	 	 
	 	

Great Point Partners, LLC

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin  	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

BIOMEDICAL VALUE FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

BIOMEDICAL INSTITUTIONAL VALUE FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

BIOMEDICAL OFFSHORE VALUE FUND, LTD.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

  

2

  

 

	 	

WS INVESTMENTS III, LLC

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

DAVID J. MORRISON

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

CLASS D SERIES OF GEF-PS, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Managing Director	 

 

	 	

LYRICAL MULTI-MANAGER FUND, L.P.

By:  Great Point Partners, LLC, its investment manager

	 
	 	 	 	 
	
 

	
By: 

	/s/ David E. Kroin 	 
	 	 	Name:	David E. Kroin	 
	 	 	Title:	Title:  Managing Director	 

 

  

3

  

 

	 	

DEERFIELD SPECIAL SITUATION FUND, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

	 	

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL, LIMITED

	 
	 	 	 	 
	
 

	
By: 

	/s/ James E. Flynn	 
	 	 	Name:	James E. Flynn	 
	 	 	Title:	Director	 
	 	 	 	 

 

	 	

DEERFIELD PRIVATE DESIGN FUND II, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

	 	

DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

	 
	 	By: 	Deerfield Capital, L.P.	 
	 	 	General Partner	 
	 	 	By: 	J.E. Flynn Capital, LLC	 
	 	 	 	General Partner	 
	 	 	 	 
	
 

	 	 	

By: 

	/s/ James E. Flynn	 
	 	 	 	 	Name:	James E. Flynn	 
	 	 	 	 	Title:	President	 
	 	 	 	 

 

  

4

  

 

	 	

THE SHIVJI FAMILY TRUST DATED JUNE 12, 2000

	 
	 	 	 	 
	
 

	
By: 

	/s/ Alnoor Shivji 	 
	 	 	Name:	Alnoor Shivji	 
	 	 	Title:	Trustee	 
	 	 	 	 

  

5

  

 

 

	 	

COMPANY MANAGEMENT:

	 
	 	 	 	 
	
 

	
 

	/s/ Alnoor Shivji	 
	 	 	Name:	Alnoor Shivji	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Robert Coradini    	 
	 	 	Name:	Robert Coradini	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Robert Hariri  	 
	 	 	Name:	Dr. Robert J. Hariri	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Dean Hautamaki  	 
	 	 	Name:	Dr. R. Dean Hautamaki	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Makoto Kaneshiro  	 
	 	 	Name:	Makoto Kaneshiro	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Joel Kanter	 
	 	 	Name:	Joel Kanter	 
	 	 	 	 	 

 

	
 

	
 

	/s/ Timothy Triche	 
	 	 	Name:	Dr. Timothy Triche	 
	 	 	 	 	 

 

 

	

Accepted and agreed:

WaferGen Bio-systems, Inc.

	 
	 	 	 
	
By: 

	/s/ Alnoor Shivji 	 
	 	Name:	Alnoor Shivji	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	 	cc:  	Morrison & Foerster LLP	 
	 	 	425 Market Street	 
	 	 	San Francisco, CA  94105	 
	 	 	Attention:  John M. Rafferty, Esq.	 

  

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]